NASDAQ:OCUP
Delisted

Ocuphire Pharma Stock Signals

etoro logo Buy OCUP
*Your capital is at risk
$1.17
+0 (+0%)
At Close: Jan 22, 2025

Latest Data & Signals Issued

Below are some of the latest signals issued for Ocuphire Pharma, Inc.

General

Signal Type Signal Value Data
Score 0.000 59 days ( 0 %
Last Price $1.17 0 %
Performance History
7 Days
$1.17 $1.17
0%
30 Days
$1.17 $1.17
0%
12 Mos
$2.73 $1.17
-57.14%

4/18

Active Buy Signals

Specific Signals

Short Term
Net score: 20.95
Signal Type Signal Value Importance Data
High / Low N/A Very Low $1.17 - $1.17
Trend - 3 mos 0 % High Width: 0 %
Pred. range - 3 mos N/A - N/A Low -100.00 % - -100.00 %
Volume Direction Sell High Volume: 1 · Direction: 0
Pivot Short Buy Very Low Jan 21, 2025 - 2 days
RSI Short Pivot Signal Buy Very Low Nov 07, 2024 - 50 days
Short MA 3 mos Sell Low Nov 30, -0001 - N/A days
Long MA 3 mos Sell Medium Nov 30, -0001 - N/A days
Short/Long MA 3 mos Sell Medium Nov 30, -0001 - N/A days

Unlock Short Term Signals

Get access to powerful short-term trading signals and real-time market insights

Subscribe Now
Long Term
Net score: 16.93
Signal Type Signal Value Importance Data
Trend - 12 mos -51.05 % Very High Width: 219.10 %
Pred. range - 12 mos $0.211 - $0.673 High -81.97 % - -42.45 %
Short MA 12 mos Sell Very High Oct 22, 2024 - 62 days
Long MA 12 mos Sell Very High Aug 01, 2024 - 119 days
Short/Long MA 12 mos Sell Very High Aug 16, 2024 - 108 days
Pivot Long Buy Low Oct 23, 2024 - 61 days
RSI Long Pivot Signal Buy Low Nov 18, 2024 - 43 days
Bollinger Sell Medium Nov 30, -0001 - N/A days
MACD Neutral High No Dates Stored For This Signal
Click to get the best stock tips daily for free!
ABOUT OCUPHIRE PHARMA, INC.
Ocuphire Pharma
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induc...
GOLDEN STAR
Ticker Change Signal Date
LITE
$905.00
4.43% Jun 01
N
NVRI
$19.53
0.87% May 20
RUN
$12.83
15.51% May 06
GLBE
$31.61
4.05% May 05
SAP
$172.39
8.56% May 05

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE